Skip to content

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: A review of systematic reviews

Research output: Contribution to journalArticle

Original languageEnglish
Article number275
Number of pages13
JournalBMC Psychiatry
Volume18
Issue number1
DOIs
DateAccepted/In press - 13 Aug 2018
DatePublished (current) - 3 Sep 2018

Abstract

Background: There is conflicting evidence on the association between antipsychotic polypharmacy and metabolic syndrome in schizophrenia. We conducted a review of published systematic reviews to evaluate evidence on the association between metabolic syndrome (diabetes, hypertension, and hyperlipidaemia) and exposure to antipsychotic polypharmacy in schizophrenia. Methods: We searched five electronic databases, complemented by reference screening, to find systematic reviews that investigated the association of antipsychotic polypharmacy in schizophrenia with hypertension, diabetes, or hyperlipidaemia. Selection of reviews, data extraction and review quality were conducted independently by two people and disagreements resolved by discussion. Results were synthesised narratively. Results: We included 12 systematic reviews, which reported heterogeneous results, mostly with narrative syntheses and without pooled data. The evidence was rated as low quality. There was some indication of a possible protective effect of drug combinations including aripiprazole for diabetes and hyperlipidaemias, compared to other combinations and/or monotherapy. Only one review reported the association between APP and hypertension. The most frequently reported combinations of medication included clozapine, possibly representing a sample of patients with treatment resistant illness. No included review reported results separately by setting (primary or secondary care). Conclusions: Further robust studies are needed to elucidate the possible protective effect of aripiprazole. Long-term prospective studies are required for accurate appraisal of diabetes risk, hypertension and hyperlipidaemia in patients exposed to antipsychotic polypharmacy.

    Research areas

  • Schizophrenia, Antipsychotics, Diabetes mellitus, Metabolic syndrome

Download statistics

No data available

Documents

Documents

  • Full-text PDF (final published version)

    Rights statement: This is the final published version of the article (version of record). It first appeared online via BioMed Central at https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-018-1848-y . Please refer to any applicable terms of use of the publisher.

    Final published version, 739 KB, PDF document

    Licence: CC BY

DOI

View research connections

Related faculties, schools or groups